Clinical trial NCT07091747
Status: Active, not recruitingPhase 1/2Latest change: Source: ClinicalTrials.gov
What's on this page?
Information in the record
Original title: Use of a Product Containing the Cannabinoids CBD and THC as a Treatment Strategy for Alzheimer's Disease - Alzheimer's Disease and Cannabis Clinical Trial (DAZACANN) Open-Label Phase
- Record number
- NCT07091747
- Status
- Active, not recruiting
- Type and phase
- Clinical trial, phase 1/2
- Participants
- 61 (actual)
- Condition (as registered)
- Alzheimer Disease (AD)
- Countries
- Brazil
- Topic in the guide
- Dementia
Timeline
According to the ClinicalTrials.gov record. Future dates are the investigator’s estimates and may change.
- Start: April 7, 2025
- End of data collection for primary results: December 12, 2025
- Trial completion: December 12, 2025
History
We check the record every day; here are the changes we have seen since we started tracking it, newest first.
- : Added to tracking. Status: Active, not recruiting.
Results
No results have been published yet. When they are, they will appear here. A trial being under way does not mean CBD works for this condition; only the results can show that.
All ongoing trials · Dementia: ongoing trials · Thinking of taking part? Which specialist to see